Mild cognitive impairment: Potential pharmacological treatment options

Journal of the American Geriatrics Society

Volumn 48, Issue 4, 2000, Pages 431-441

  Sherwin, Barbara B ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Acetylcholinesterase inhibitors; Age associated memory impairment; Estrogen; Mild cognitive impairment; Nootropic agents

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; ERGOT ALKALOID; ESTROGEN; GLUTAMATE RECEPTOR; NEUROPEPTIDE; NOOTROPIC AGENT;

AGING; AMNESIA; ARTICLE; COGNITION; COGNITIVE DEFECT; DIAGNOSTIC TEST; DRUG EFFECT; HUMAN; NEUROPSYCHOLOGICAL TEST; RATING SCALE; WORKING MEMORY;

EID: 0034079660     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2000.tb04703.x     Document Type: Article

References (163)

1. Scheibel AB. Structural and functional changes in the aging brain. In: Birren JE, Schaie KW, eds. Handbook of the Psychology of Aging, 4th Ed. San Diego: Academic Press, Inc, 1996, pp 105-128.
2. Terry RD, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol 1987;21:530-539.
3. Kral VA. Senescent forgetfulness: Benign and malignant. Can Med Assoc J 1962;86:257-260.
4. Crook T, Bartus RT, Ferris SH et al. Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change - Report of a National Institute of Mental Health Work Group. Rev Neuropsychol 1986; 2:261-276.
5. Blackford RC, La Rue A. Criteria for diagnosing age-associated memory impairment: Proposed improvements from the field. Dev Neuropsychol 1989;5:295-306.
6. Levy R. Aging-associated cognitive decline. Int Psychogeriatr 1994;6:63-68.
7. Smith GE, Petersen RC, Parisi JE et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cognition 1996;3:141-147.
8. Almkvist O, Basun H, Backman I. et al. Mild cognitive impairment: An early stage of Alzheimer's disease? J Neural Transm 1998;54:21-29.
9. Small GW. Treatment of Alzheimer's disease: Current approaches and promising developments. Am J Med 1998;104(suppl 4A):32-38S.
10. Schonfield D, Robertson B. Memory storage and aging. Can J Psychol 1966;20:228-236.
11. Craik FIM. Age differences in human memory. In: Birren JK, Schaie KW, eds. Handbook of the Psychology of Aging. New York: Van Nostrand Reinhold, 1977, pp 384-420.
12. White N, Cunningham WR. What is the evidence for retrieval problems in the elderly? Exp Aging Res 1982;8:169-171.
13. Erber JT. Age differences in recognition memory. J Gerontol 1974;29:177-181.
14. Kausler DH. Associative strength and paired-associate learning in elderly subjects. J Gerontol 1966;21:278-280.
15. Gilbert JG, Levee RE. Patterns of declining memory. J Gerontol 1971;26: 70-75.
16. Thomas JC, Ruben H. Age and mnemonic techniques in paired-associate learning. Presented at the meeting of the Gerontological Society of America, Miami, FL, November 5-9, 1973.
17. Smith AD. Aging and interference with memory. J Gerontol 1975;30:319-325.
18. Rabinowitz JC. Aging and recognition failure. J Gerontol 1984;39:65-71.
19. Albert M, Duffy FH, Naeser M. Nonlinear changes in cognition with age and their neuropsychologic correlates. Can J Psychol 1987;41:141-157.
20. Wingfield A, Stine EAL, Lahar CJ et al. Does the capacity of working memory change with age? Exp Aging Res 1988;14:103-107.
21. Salthouse TA, Babcock RL. Decomposing adult age differences in working memory. Dev Psychol 1991;27:763-776.
22. Dobbs AR, Rule BG. Adult age differences in working memory. Psychol Aging 1989;4:500-503.
23. Morris RG, Craik FIM, Gick ML. Age differences in working memory tasks: The role of secondary memory and the central executive system. Q J Exp Psychol 1990;42A:67-86.
24. Kendall BS. Memory-for-designs performance in the seventh and eighth decades of life. Percept Mot Skills 1962;14:399-405.
25. Davies ADM. Age and memory-for-designs test. Br J Soc Clin Psychol 1967;6:228-233.
26. Botwinick J, Storandt M. Memory, Related Functions, and Age. Springfield, IL: Charles C. Thomas, 1974.
27. Bromley DB. Some effects of age on short term learning and remembering. J Gerontol 1958;13:398-406.
28. Bartlett JC, Leslie JE, Tubbs A et al. Aging and memory for pictures of faces. Psychol Aging 1989;4:276-283.
29. Drachman DA, Leavitt J. Memory impairment in the aged: Storage versus retrieval deficit. J Exp Psychol 1972;93:302-308.
30. Talland GA. Three estimates of the word span and their stability over the adult years. Q J Exp Psychol 1965;17:301-307.
31. Light LL, Singh A, Capps JL. Dissociation of memory and awareness in young and older adults. J Clin Exp Neuropsychol 1986;8:62-74.
32. Light LL, Singh A. Implicit and explicit memory in young and older adults. J Exp Psychol Learn Mem Cogn 1987;13:531-541.
33. Chiarello C, Hoyer WJ. Adult age differences in implicit and explicit memory: Time course and encoding effects. Psychol Aging 1988;3:358-366.
34. Chiarello C, Hoyer WJ, Frazier L. Encoding conditions and implicit memory in young and elderly adults. J Clin Exp Neuropsychol (abstr) 1987;9: 37.
35. Tuokko H, Hadjistavropoulos T. An Assessment Guide to Geriatric Neuropsychology. Mahwah, NJ: Lawrence Erlbaum Associates, 1998.
36. Wechsler D. WAIS-R Manual. Wechsler Adult Intelligence Scale -Revised. New York: The Psychological Corporation, 1981.
37. Franzen MD, Robbins DE, Sawicki RF. Reliability and Validity in Neuropsychological Assessment. New York: Plenum Press, 1989.
38. Gregory RJ. Adult Intellectual Assessment. Boston, MA: Allyn and Bacon, Inc., 1987.
39. Benton AL. Revised Visual Retention Test: Clinical and Experimental Applications, 4th Ed. New York: The Psychological Corporation, 1974.
40. Rev A. L'Examen Clinique en Psychologie, 2nd Ed. Paris: Presses Universitaires de France, 1964.
41. Lezak MD Neuropsychological Assessment. New York: Oxford University Press, 1983.
42. Bigler ED. Diagnostic Clinical Neuropsychology. Austin, TX: University of Texas Press, 1998.
43. Larrabee GJ, McEntee WJ. Age-associated memory impairment: Sorting out the controversies. Neurology 1995;45:611-614.
44. Dawe B, Procter A. Concepts of mild memory impairment in the elderly and their relationship to dementia - A review. Int J Geriatr Psychiatry 1992;7:473-479.
45. Petersen RC, Smith GE, Waring SC et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303-308.
46. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly. Results from the Canadian study of health and aging. Arch Neurol 1995;52:612-619.
47. Schröder J, Kratz B, Pantel J et al. Prevalence of mild cognitive impairment in an elderly community sample. J Neural Transm 1998;54(suppl):51-59.
48. Coria F, de Caso JAG, Minguez L et al. Prevalence of age-associated memory impairment and dementia in a rural community. J Neurol Neurosurg Psychiatry 1993;56:973-976.
49. Lane F, Snowdon J. Memory and dementia: A longitudinal survey of suburban elderly. Clin Abnorm Psychol 1989;365-376.
50. Koivisto K, Reinikamen KJ, Hänninen T et al. Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology 1995;45:741-747.
51. Hanninen T, Soininen H. Age-associated memory impairment: Normal aging or warning of dementia? Drugs Aging 1997;11:480-489.
52. Parnetti L, Lowenthal DT, Presciutti O et al. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J Am Geriatr Soc 1996;44:133-138.
53. Forstl H, Hentschel F, Sattel H et al. Age-associated memory impairment and early Alzheimer's disease: Only time will cell the difference. Arzneimittelforschung 1995;45:394-397.
54. Jack CRJ, Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52: 1397-1403.
55. Friedrich MJ. Mild cognitive impairment raises Alzheimer disease risk. JAMA 1999;282:621-622.
56. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: Predictors of dementia. Neurology 1991;41:1006-1009.
57. Reisberg B, Ferris SH, de Leon MJ et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139: 1136-1139.
58. Buschke H. Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 1973;12:543-550.
59. Glober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol 1987;3:13-36.
60. McKelvey R, Bergman H, Stern J et al. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 1999;26:23-28.
61. Price JL, Morris JC. Tangles and plaques in nondemented aging and "pre-clinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
62. van Reekum R, Black SE, Conn D et al. Cognition-enhancing drugs in dementia: A guide to the near future. Can J Psychiatry 1997;42(suppl 1):35-50S.
63. Riedel WJ, Jolles J. Cognitive enhancers in age-related cognitive decline. Drugs Aging 1996;8:245-274.
64. McEwen BS, Alves SE, Bulloch K et al. Ovarian steroids and the brain: Implications for cognition and aging. Neurology 1997;48:S8-S15.
65. Brinton RD, Tran J, Proffitt P et al. 17β-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res 1997;22: 1339-1351.
66. Woolley CS, McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rar. J Neurosci 1992; 12:2549-2554.
67. Wong M, Moss RL. Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA 1 neurons. J Neurosci 1992;12:3217-3225.
68. Luine VN, Khylchevskaya RI, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 1975;86:293-306.
69. Sparks DL, Hunsaker JCI, Slevin JT et al. Monoaminergic and cholinergic synaptic markets in the nucleus basalis of meynert (nbM): Normal age-related changes and the effect of heart disease and Alzheimer's disease. Ann Neurol 1992;31:611-620.
70. Perry EK, Tomlinson BE, Blessed G et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459.
71. Sims NR, Bowen DM, Smith CCT et al. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1980;1:333-336.
72. Geula C, Mesulam MM. Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study. Neuroscience 1989;33:469-481.
73. Cohen BM, Renshaw PF, Stoll AL et al. Decreased brain choline uptake in older adults, An in vivo proton magnetic resonance spectroscopy study. JAMA 1995;274:902-907.
74. Robinson D, Friedman L, Marcus R et al. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 1994;42:919-922.
75. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83:979-983.
76. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: A possible protective effect? Neurology 1997;49:1491-1497.
77. Zonderman AB, Giambra LM, Arenberg D et al. Changes in immediate visual memory predict cognitive impairment. Arch Clin Neuropsychol 1995;10:111-123.
78. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav 1995;29:312-321.
79. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea & Febiger, 1983.
80. Jacobs DM, Tang M-X, Stern Y et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368-373.
81. Carlson LE, Sherwin BB, Steroid hormones, memory and mood in a healthy elderly population. Psychoneuroendocrinology 1998;23:583-603.
82. Zakzanis KK, Leach L, Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol Behav Neurol 1998;11:111-119.
83. Paganini-Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc 1996;44:818-822.
84. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993;269:2637-2641.
85. Matthews K, Cauley J, Yaffe K et al. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999;47: 518-523.
86. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-318.
87. Caldwell BM, Watson RI. An evaluation of psychologic effects of sex hormone administration in aged women. I. Results of therapy after six months. J Gerontol 1952;7:228-244.
88. Caldwell BM. An evaluation of psychological effects of sex hormone administration in aged women. II. Results of therapy after eighteen months. J Gerontol 1954;9:168-174.
89. Hackman BW, Galbraith D. Replacement therapy with piperazine oestrone sulphate ('Harmogen') and its effect on memory. Curr Med Res Opin 1976; 4:303-305.
90. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-357.
91. Fedor-Freybergh P. The influence of oestrogens on the well-being and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl 1977;64:1-92.
92. Shaywitz SE, Shaywitz BA, Pugh KR et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-1202.
93. Phillips SM, Sherwin BB. Effects on estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
94. Sherwin BB, Phillips S. Estrogen and cognitive functioning in surgically menopausal women. Ann N Y Acad Sci 1990;592:474-475.
95. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545-2549.
96. Rauramo L, Lagerspetz K, Engblom P et al. The effect of castration and peroral estrogen therapy on some psychological functions. Horm Res 1975; 3:94-104.
97. Vanhulle G, Demol R. A double-blind study into the influence of estriol on a number of psychological tests in post-menopausal women. In: van Keep PA, Greenblatt RB, Albeaux-Fernet M, eds. Consensus on Menopause Research: A Summary of International Opinion. Baltimore, MD: University Park Press, 1976, pp 94-99.
98. Ditkoff EC, Crary WG, Cristo M et al. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991; 78:991-995.
99. Hol T, Cox MB, Bryant HU et al. Selective estrogen receptor modulators and postmenopausal women's health. J Womens Health 1997;6:523-531.
100. Bryant HU, Bales KR, Paul SM et al. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain. Society Neurosci (abstract) 1997;23:2377.
101. Meisel RL, Dohanich GP, McEwen BS et al. Antagonism of sexual behavior in female rats by ventromedial hypothalamic implants of antiestrogen. Neuroendocrinology 1987;45:201-207.
102. Petersen SL, Barraclough CA. Suppression of spontaneous LH surges in estrogen-treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain. Brain Res 1989;484:279-289.
103. Shughrue PJ, Lane MV, Merchenthaler I. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: An in situ hybridization study. Endocrinology 1997;138:5476-5484.
104. Nickelsen T, Lufkin EG, Riggs BL et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects of cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999;24:115-128.
105. Zorumski CF, Izumi Y. Modulation of LTP induction by NMDA receptor activation and nitric oxide release. Prog Brain Res 1998;118:173-182.
106. Lynch G. Memory and the brain: Unexpected chemistries and a new pharmacology. Neurobiol Learn Mem 1998;70:82-100.
107. Meyer RC, Spangler EL, Kametani H et al. Age-related memory impairment: Assessing the role of nitric oxide. Ann N Y Acad Sci 1999;854:307-317.
108. Gazzaley AH, Siegel SJ, Kordower JH et al. Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys. Proc Natl Acad Sci USA 1996;93:3121-3125.
109. 3H]MK-801 binding in the Fischer 344 rat brain. Neurobiol Aging 1998;19:259-265.
110. Ingram DK, Shimada A, Spangler EL et al. Cognitive enhancement: New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ann N Y Acad Sci 1996;786:348-361.
111. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991;14:60-67.
112. Estall LB, Grant SJ, Cicala GA. Inhibition of nitric oxide (NO) production selectivity impairs learning and memory in the rat. Pharmacol Biochem Behav 1993;46:959-962.
113. Pelleymounter MA, Beatty G, Gallagher M. Hippocampal 3H-CPP binding and spatial learning deficits in aged rats. Psychobiology 1990;18:298-304.
114. McEntee WJ, Crook TH. Glutamate: Its role in learning, memory, and the aging brain. Psychopharmacology 1993;111:391-401.
115. Schwartz BL, Hashtroudi S, Herting RL et al. Glycine prodrug facilitates memory retrieval in humans. Neurology 1991;41:1341-1343.
116. Schwartz BL, Hashtroudi S, Herting RL et al. The effects of milacemide on item and source memory. Clin Neuropharmacol 1992;15:114-119.
117. Bowles NL, Poon LW. Aging and retrieval of words in semantic memory. J Gerontol 1985;40:71-77.
118. Saletu B, Grünberger J, Linzmayer L. Acute and subacute CNS effects of milacemide in elderly people: Double-blind, placebo-controlled quantitative EEG and psychometric investigations. Arch Gerontol Geriatr 1986;5:165-181.
119. Lynch G, Granger R, Ambros-Ingerson J et al. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 1997;14.5:89-92.
120. Giurgea C. The "nootropic" approach to the pharmacology of the integrative activity of the brain. Cond Reflex 1973;8:108-115.
121. Vernon MW, Sorkin EM. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1991;1:17-35.
122. Mindus P, Cronholm B, Levander SE et al. Piracetam-induced improvement of mental performance: A controlled study on normally aging individuals. Acta Psychiatr Scand 1976;54:150-160.
123. Fioravanti M, Bergamasco B, Bocola V et al. A multicentre, double-blind, controlled study of piracetam vs placebo in geriatric patients with nonvascular mild-moderate impairment on cognition. New Trends Clin Neuropharmacol 1991;5:27-34.
124. Randt CT, Brown ER, Osborne DP Jr. A memory test for longitudinal measurement of mild to moderate deficits. Clin Neuropsychol 1980;2:184-194.
125. Fioravanti M, Thorel M, Ramelli L et al. Reliability between the five forms of the Randt memory test and their equivalence. Arch Gerontol Geriatr 1985;4:357-364.
126. Marini G, Caratti C, Peluffo F et al. Placebo-controlled double-blind study of pramiracetam (CI-879) in the treatment of elderly subjects with memory impairment. Adv Ther 1992;9:136-146.
127. Sheffield LG, Berman NE. Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiol Aging 1998;19:47-55.
128. Sheng JG, Mrak RE, Griffin WST. Enlarged and phagocytic, but not primed, interleukin-1α-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol 1998;95:229-234.
129. Halliwell B. Oxygen radicals as key mediators in neurological disease: Fact or fiction? Ann Neurol 1992;32(suppl):S10-15.
130. Harman D. Role of free radicals in aging and disease. Ann N Y Acad Sci 1992;673:126-141.
131. Weldon DT, Maggio JE, Mantyh PW. New insights into the neuropathology and cell biology of Alzheimer's disease. Geriatrics 1997;52(suppl 2): S13-16.
132. Mrak RE, Griffin WST, Graham DI. Aging-associated changes in human brain. J Neuropathol Exp Neurol 1997;56:1269-1275.
133. West MJ. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 1993;14:287-293.
134. McGeer PL, McGeer E, Rogers J et al. Anti-inflammatory drugs and Alzheimer disease. Lancet (letter) 1990;335:1037.
135. McGeer PL, McGeer EG. The inflammatory response system of the brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
136. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
137. Breitner JCS, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a cotwin study. Neurology 1994;44:227-232.
138. Henderson AS, Jorm AF, Christensen H et al. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 1997;12:926-930.
139. Saag KG, Rubenstein LM, Chrischilles EA et al. Nonsteroidal antiiflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995;22:2142-2147.
140. Rosler M, Retz W, Thome J et al. Free radicals in Alzheimer's dementia: Currently available therapeutic strategies. J Neural Transm 1998;54(suppl): 211-219.
141. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997;45: 718-724.
142. Packer L, Haramaki N, Kawabata T et al. Ginkgo biloba extracts (EGb 761): Antioxidant action and prevention of oxidative stress-induced injury. In: Christen Y, Courtois Y, Droy-Lefaix M-T, eds. Effects of Ginkgo Biloba Extract (EGb 761) on Aging and Age-Related Disorders. Paris: Elsevier, 1995, pp 23-47.
143. White HL, Scates PW, Cooper BR. Extracts of ginkgo biloba leaves inhibit monoamine oxidase. Lite Sci 1996;58:1315-1321.
144. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 1994;9:215-222.
145. Kanowski S, Herrmann WM, Stephan K et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
146. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
147. Mair RG, McEntee WJ. Cognitive enhancement in Korsakoff's psychosis by clonidine: A comparison with L-dopa and ephedrine. Psychopharmacology 1986;88:374-380.
148. McEntee WJ, Mair RG. Memory enhancement in Korsakoff's psychosis by clonidine: Further evidence for a noradrenergic deficit. Ann Neurol 1980;7: 466-470.
149. McEntee WJ, Crook TH, Jenkyn LR et al. Treatment of adult-onset cognitive disorders: Results of multicenter trials. Psychopharmacol Bull 1991;27: 41-46.
150. Poitrenaud J, Piette F, Malbezin M et al. Almitrine-raubasine and cognitive impairment in the elderly: Results of a 6-month controlled multicenter study. Clin Neuropharmacol 1990;13:S100-108.
151. Wadworth AN, Chrisp P. Co-dergocrine mesylate: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging 1992;2:153-173.
152. McDonald RJ. Hydergine: A review of 26 clinical studies. Pharmakopsychiatria 1979;12:407-422.
153. Spiegel R, Huber F, Koberle S. A controlled long-term study with ergoloid mesylates (Hydergine) in healthy, elderly volunteers: Results after three years. J Am Geriatr Soc 1983;31:549-555.
154. de Wied D, van Ree JM. Neuropeptides, mental performance and aging. Life Sci 1982;31:709-719.
155. Weingartner H, Kaye W, Gold P et al. Vasopressin treatment of cognitive dysfunction in progressive dementia. Life Sci 1981;29:2721-2726.
156. Peabody CA, Thiemann S, Pigache R et al. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia. Neurobiol Aging 1985;6:95-100.
157. Nebes RD, Renolds CFI, Horn LC. The effect of vasopressin on memory in the healthy elderly. Psychiatry Res 1984;11:49-59.
158. Perras B, Droste C, Born J et al. Verbal memory after three months of intranasal vasopressin in healthy old humans. Psychoneuroendocrinology 1997;22:387-396.
159. Hijman R, Jolles J, Verhoeven WMA et al. Desglycinamide-(Arg8)-vasopressin in five trials with memory-disturbed patients. Hum Psychopharmacol 1992;7:7-23.
160. Fehm-Wolfsdorf G, Born J. Behavioral effects of neurohypophyseal peptides in healthy volunteers: 10 years of research. Peptides 1991;1406.
161. Whitehouse PJ, Price DL, Struble RG et al. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
162. Richter JA, Perry EK, Tomlinson BE. Acetylcholine and choline levels in post-mortem human brain tissue: Preliminary observations in Alzheimer's disease. Life Sci 1980;26:1683-1689.
163. Shoupe D. Hormone replacement therapy: Reassessing the risks and benefits. Hosp Pract 1999;34:97-114.